HighTower Advisors LLC Acquires 350 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

HighTower Advisors LLC raised its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 9.1% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 4,179 shares of the biopharmaceutical company’s stock after buying an additional 350 shares during the quarter. HighTower Advisors LLC’s holdings in Intra-Cellular Therapies were worth $349,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the business. The Manufacturers Life Insurance Company raised its position in shares of Intra-Cellular Therapies by 1.3% during the third quarter. The Manufacturers Life Insurance Company now owns 22,057 shares of the biopharmaceutical company’s stock valued at $1,614,000 after buying an additional 283 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Intra-Cellular Therapies by 13.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 22,522 shares of the biopharmaceutical company’s stock valued at $1,648,000 after purchasing an additional 2,622 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Intra-Cellular Therapies by 3.6% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 323,208 shares of the biopharmaceutical company’s stock valued at $23,649,000 after purchasing an additional 11,104 shares in the last quarter. Captrust Financial Advisors lifted its position in Intra-Cellular Therapies by 47.0% in the third quarter. Captrust Financial Advisors now owns 8,050 shares of the biopharmaceutical company’s stock worth $589,000 after purchasing an additional 2,572 shares during the period. Finally, Erste Asset Management GmbH acquired a new stake in Intra-Cellular Therapies during the third quarter worth $1,715,000. 92.33% of the stock is currently owned by institutional investors and hedge funds.

Intra-Cellular Therapies Stock Down 0.0 %

Shares of ITCI stock opened at $131.87 on Wednesday. The firm has a market cap of $14.05 billion, a price-to-earnings ratio of -151.57 and a beta of 0.69. Intra-Cellular Therapies, Inc. has a 12 month low of $64.09 and a 12 month high of $131.98. The stock has a 50-day moving average price of $129.34 and a 200 day moving average price of $100.60.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The business had revenue of $199.22 million for the quarter, compared to analyst estimates of $205.08 million. Sell-side analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Leerink Partnrs downgraded shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. StockNews.com began coverage on Intra-Cellular Therapies in a report on Friday, March 28th. They set a “hold” rating on the stock. Piper Sandler reissued a “neutral” rating and issued a $132.00 target price (up from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Mizuho lowered Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and decreased their price target for the company from $140.00 to $132.00 in a research note on Monday, February 24th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Intra-Cellular Therapies in a research note on Friday, February 21st. Ten investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $106.08.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.